| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00931762 Details | 2021-07-30 Interventional | 2 | [1 Refs] | 35 | Panobinostat Polycythemia Polycythemia Ve… Primary Myelofi… Thrombocytopeni… Post-Essential … Post-Polycythem… | - - | ||
| NCT00473824 Details | 2021-07-30 Interventional | 2 | 7 | Antibodies Immunoglobulins Immunoglobulins… Rho(D) Immune G… gamma-Globulins Hepatitis Hepatitis A Hepatitis C Evidence of Liv… Sequelae of Vir… Transplantation… | New sponsor's decision to pursue a redesigned clinical study Early termination by sponsor due to data from the initial 7 patients of 36 planned for this study. Therefore, statistical analysis was not performed and no conclusion were reached regarding efficacy or drug safety. | |||
| NCT04764383 Details | 2021-07-29 Interventional | 2 | 0 | Histamine Fatigue Multiple Sclero… Sclerosis | Withdrawn as more data drug analysis is recommended before the study. - | |||
| NCT03033511 2016-003503-64 Details | 2021-07-29 Interventional | 3 | 748 | BB 1101 Dexamethasone Dexamethasone a… Immunoconjugate… Rovalpituzumab … Lung Neoplasms Small Cell Lung… Small Cell Lung… | Independent Data Monitoring Committee recommendation - | |||
| NCT01812135 Details | 2021-07-29 Interventional | 2 | 0 | Vaccines Virus Diseases Infection, Vira… | Based on the previous study results, inactivated EV71 vaccine with aluminum adjuvant was
elected to be used for the efficacy Phase III study. - | |||
| NCT01440062 Details | 2021-07-29 Interventional | 2 | 55 | Cholecalciferol Ergocalciferols Vitamin D Vitamins Multiple Sclero… Sclerosis | - - | |||
| NCT00860379 Details | 2021-07-29 Interventional | 4 | 14 | Selenium Burns | Due to a shift in primary responsibilities, the PI was not longer able to enroll subjects. - | |||
| NCT04906876 Details | 2021-07-28 Interventional | 2 | 0 | Docetaxel Gemcitabine Hemangiosarcoma Histiocytoma, M… Leiomyosarcoma Liposarcoma Rhabdomyosarcom… Sarcoma Sarcoma, Synovi… Angiosarcoma Bone Sarcoma High Grade Sarc… Metastatic Sarc… Myxofibrosarcom… Soft Tissue Sar… Spindle Cell Sa… Synovial Sarcom… Undifferentiate… | IND withdrawn - | |||
| NCT04136444 Details | 2021-07-28 Interventional | 1 | 12 | Padsevonil Healthy Study P… Impaired Hepati… | Based on available data, UCB has decided to stop development of padsevonil as adjunctive
treatment of focal-onset seizures - | |||
| NCT03486353 Details | 2021-07-27 Interventional | 2 | 0 | Azacitidine Myelodysplastic… Preleukemia Syndrome Myelodysplastic… | Program terminated - | |||
| NCT02930343 Details | 2021-07-27 Interventional | 3 | 136 | Folic Acid Glucocorticoids Hydroxychloroqu… Leflunomide Methotrexate Prednisolone Sulfasalazine Arthritis Arthritis, Rheu… Rheumatoid Arth… | Due to time constraints, the study was halted prematurely Early termination resulted in enrollment of 136 patients instead of 140 patients. | |||
| NCT04584034 Details | 2021-07-23 Interventional | 4 | 0 | Albuterol Bronchodilator … Respiratory Sou… Wheezing | Premature ending of the study due to impossibility of obtaining a suitable placebo-inhaler - | |||
| NCT04474210 Details | 2021-07-23 Interventional | 1 | 1 | JNJ-56136379 Renal Insuffici… | Strategic Decision - | |||
| NCT03277352 Details | 2021-07-22 Interventional | 1/2 | 10 | Pembrolizumab Neoplasms Advanced Malign… Metastatic Canc… | The study was terminated due to emergent data from another study and unrelated to safety. - | |||
| NCT02476994 Details | 2021-07-21 Interventional | 4 | 1 | Soybean oil, ph… Essential Fatty… | Based on feedback from FDA - | |||
| NCT04370834 Details | 2021-07-20 Interventional | 2 | 1 | Immunoglobulin … Immunoglobulins Acute Lung Inju… COVID-19 Laboratory Infe… Neoplasms Pneumonia Respiratory Dis… Respiratory Dis… Hematopoietic a… Malignant Solid… Pneumonitis Severe Acute Re… Symptomatic COV… | Other - Randomized data no longer support continuation Early termination as randomized data did not support continuation. | |||
| NCT02579863 2015-002901-12 Details | 2021-07-20 Interventional | 3 | 310 | Dexamethasone Lenalidomide Pembrolizumab Multiple Myelom… Neoplasms, Plas… | The study was terminated early due to business reasons The MK-3475-185 study was stopped/terminated early. Endpoint statistics may be biased due to the incomplete treatment and follow-up of participants after study termination | |||
| NCT04117607 Details | 2021-07-16 Interventional | 1 | 14 | Rezafungin Mycoses Fungal Infectio… | Stopped due to the formation of injection site skin nodules. - | |||
| NCT02439970 Details | 2021-07-16 Interventional | 3 | 5 | Brincidofovir Valganciclovir Cytomegalovirus… Cytomegalovirus… | Study was terminated early due to results from another CMX001 study No conclusions regarding safety or efficacy can be made from the limited data obtained in this study. Enrollment was suspended and all blinded study treatment was discontinued early January 2016. | |||
| NCT02439957 Details | 2021-07-16 Interventional | 3 | 6 | Brincidofovir Valganciclovir Cytomegalovirus… Cytomegalovirus… Kidney Transpla… | Study terminated early due to results from another CMX001 study. The study was terminated. Enrollment was suspended and all blinded study treatment was discontinued in early January 2016. No conclusions can be made from this study. |